ClinicalTrials.gg
CompletedNCT00651261Updated Oct 21, 2026Results posted

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

A Phase 3 interventional study of cytarabine and daunorubicin in Leukemia, sponsored by Alliance for Clinical Trials in Oncology. Completed at 176 sites in 2 countries. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's title name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
717
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing midostaurin in Leukemia, Myeloid, Acute — 3 open to participants now, 5 under way, 1 of them phase 3. midostaurin · Leukemia, Myeloid, Acute.

Enrollment
2nd of 28
717 · median 34
Started
2008
the only one that year
Phase 3
4 of 28
1 open now
Registered
3rd of 28
by date
Lead sponsor
1 of 28
Alliance for Clinical Trials in Oncology

Among the 28 studies testing midostaurin in Leukemia, Myeloid, Acute, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 4 in phase 3, and was the 3rd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

3 of the 28 studies testing midostaurin in Leukemia, Myeloid, Acute are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About midostaurin

midostaurin: first FDA approval 2017 (RYDAPT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing midostaurin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of illnesses, including AML, colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells with the abnormal FLT3 gene.

Read the detailed description

In this study, patients will receive either the experimental agent (midostaurin) or placebo combined with chemotherapy treatment. Patients are stratified according to FLT3 mutation status (internal tandem duplication [ITD] allelic ratio \< 0.7 vs ITD allelic ratio ≥ 0.7 vs tandem kinase domain [TKD]). There are three parts to the study treatment: remission induction therapy, remission consolidation therapy and continuation therapy.

Remission Induction Therapy:

  • Cytarabine 200 mg/m2/day by continuous intravenous infusion on days 1-7
  • Daunorubicin 60 mg/m2/day by intravenous push or short infusion on days 1-3
  • Midostaurin 50 mg (two 25 mg capsules) or placebo for midostaurin (2 capsules) twice a day by mouth on days 8-21
  • A bone marrow aspiration will be performed in all patients on Day 21 to determine the need for a second induction cycle.

Remission Consolidation (Four Remission Consolidation Cycles):

  • High dose cytarabine 3000 mg/m2 will be given by intravenous infusion over 3 hours every 12 hours on days 1, 3 and 5. Serial neurologic evaluation will be performed before and following the infusion of high-dose cytarabine.
  • Dexamethasone 0.1% or other corticosteroid ophthalmic solution 2 drops to each eye once daily to begin 6-12 hours prior to the initiation of the cytarabine infusion and to continue for at least 24 hours after the last cytarabine dose.
  • Midostaurin 50 mg (two 25 mg capsules) or placebo for midostaurin (2 capsules) twice a day by mouth on days 8-21

Midostaurin/Placebo Continuation Therapy:

  • Midostaurin 50 mg (two 25 mg capsules) or placebo for midostaurin (2 capsules) by mouth twice a day for 28 days. Each cycle will be 28 days in length. Continuation therapy with midostaurin/placebo will continue until relapse or for 12 cycles maximum.

The primary and secondary objectives of this study are:

Primary objective:

  • To determine if the addition of midostaurin to daunorubicin/cytarabine induction, high-dose cytarabine consolidation, and continuation therapy improves overall survival (OS) in both the mutant FLT3-ITD and FLT3-TKD AML patients

Secondary objectives:

  • To compare the overall survival (OS) in the two groups using an analysis in which patients who receive a stem cell transplant are censored at the time of transplant
  • To compare the complete response (CR) rate between the two treatment groups
  • To compare the event-free survival (EFS) between the two treatment groups
  • To compare the disease free survival (DFS) of the two treatment groups
  • To compare the disease free survival rate one year after completion of the continuation phase of the two groups
  • To assess the toxicity of the experimental combination
  • To describe the interaction between treatment outcome and pretreatment characteristics such as age, performance status, white blood cell (WBC) count, morphology, cytogenetics, and molecular and pharmacodynamic features
  • To assess the population pharmacokinetics (popPK) of midostaurin and its two major metabolites (CGP52421 and CGP62221). The potential association(s) between PK exposure and FLT3 status, OS, EFS and clinical response will be explored

There is a pharmacokinetic sub-study (CALGB 60706) within CALGB 10603. This embedded companion study must be offered to all patients enrolled on CALGB 10603, although patients may opt not to participate in CALGB 60706.

After study entry, patients are followed periodically for up to 10 years.

03

Conditions studied

  • Leukemia

Keywords

  • adult acute basophilic leukemia
  • adult acute eosinophilic leukemia
  • adult acute lymphoblastic leukemia
  • adult acute megakaryoblastic leukemia (M7)
  • adult acute minimally differentiated myeloid leukemia (M0)
  • adult acute monoblastic leukemia (M5a)
  • adult acute monocytic leukemia (M5b)
  • adult acute myeloblastic leukemia with maturation (M2)
  • adult acute myeloblastic leukemia without maturation (M1)
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • adult acute myelomonocytic leukemia (M4)
  • adult erythroleukemia (M6a)
  • adult pure erythroid leukemia (M6b)
  • untreated adult acute myeloid leukemia
04

In context

Leukemia, Myeloid, Acute Reclassified

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

This study's enrollment of 717 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Alliance for Clinical Trials in Oncology is the lead sponsor of 509 studies on the registry; 28 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Documentation of Disease:

    • Unequivocal diagnosis of AML ( > 20% blasts in the bone marrow based on the WHO classification), excluding M3 (acute promyelocytic leukemia). Patients with neurologic symptoms suggestive of CNS leukemia are recommended to have a lumbar puncture. Patients whose CSF is positive for AML blasts are not eligible.
    • Documented FLT3 mutation (ITD or point mutation), determined by analysis in a protocol- designated FLT3 screening laboratory.
  2. Age Requirement:

    • Age ≥ 18 and \< 60 years
  3. Prior Therapy:

    • No prior chemotherapy for leukemia or myelodysplasia with the following exceptions:

      • emergency leukapheresis
      • emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days
      • cranial RT for CNS leukostasis (one dose only)
      • growth factor/cytokine support
    • AML patients with a history of antecedent myelodysplasia (MDS) remain eligible for treatment on this trial, but must not have had prior cytotoxic therapy (e.g., azacitidine or decitabine)
    • Patients who have developed therapy related AML after prior RT or chemotherapy for another cancer or disorder are not eligible.
  4. Cardiac Function: Patients with symptomatic congestive heart failure are not eligible.
  5. Initial Laboratory Value: Total \< 2.5 x (Upper Limit of Normal)
  6. Pregnancy and Nursing Status:

    • Non-pregnant and non-nursing due to the unknown teratogenic potential of midostaurin in humans, pregnant or nursing patients may not be enrolled.
    • Women of must have a negative serum or urine pregnancy test within a sensitivity of at least 50 mIU/mL within 16 days prior to registration.
    • Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or commit to TWO acceptable methods of :

      • one highly effective method (eg, IUD, hormonal (non-oral contraceptive), tubal ligation, or partner's vasectomy) and
      • one additional effective method (e.g., latex condom, diaphragm or cervical cap)
    • The two acceptable methods of birth control must be used AT THE SAME TIME, before beginning midostaurin/placebo therapy and continuing for 12 weeks after completion of all therapy.
    • Note that oral contraceptives are not considered a high effective method because of the possibility of a drug interaction with midostaurin.
    • Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has not had menses at any time in the preceding 24 consecutive months.
    • Men must agree not to father a child and must use a latex condom during any sexual contact with women of childbearing potential while taking midostaurin/placebo and for 12 weeks after therapy is stopped, even if they have undergone a successful vasectomy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
717 participants (actual)

Study arms

  • Experimental
    Induction and consolidation chemotherapy plus midostaurin

    Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.

    Drug: cytarabine · Drug: daunorubicin · Drug: midostaurin · Drug: dexamethasone acetate

  • Active comparator
    Induction and consolidation chemotherapy plus placebo

    Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.

    Drug: cytarabine · Drug: daunorubicin · Other: placebo · Drug: dexamethasone acetate

Interventions

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) was defined as the time interval from randomization to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method.

    Time frame: Duration of study (Up to 10 years)

Secondary outcomes

  1. Event- Free Survival

    Event free survival (EFS) was defined as the time from randomization until the earliest qualifying event, including: failure to obtain a CR on or before 60 days of initiation of protocol therapy; relapse; or death from any cause. Patients alive and event free at the time of analysis were censored on the date of last clinical assessment. The median EFS with 95% CI was estimated using the Kaplan-Meier method. Due to a higher than expected transplant rate, EFS was promoted to be a key secondary endpoint.

    Time frame: Duration of study (Up to 10 years)

  2. Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant

    Overall survival (OS) was defined as the time interval from randomization to death from any cause. Any participants who received a stem cell transplant were censored at the time of transplant. The median OS with 95% CI was estimated using the Kaplan-Meier method.

    Time frame: Duration of study (Up to 10 years)

  3. Complete Response Rate

    Percentage of participants who achieved a complete response (CR). A CR was defined as normalization of blood counts and a marrow showing less than 5% blasts occurring on or before day 60.

    Time frame: Induction therapy (up to 60 days)

  4. Disease-free Survival (DFS)

    Disease free survival (DFS) is defined as the time from documentation of first CR at any time to the first of relapse or death from any cause in participants who achieved a CR.

    Time frame: Duration of study (Up to 10 years)

  5. DFS Rate One Year After Completing the Planned Continuation Phase

    Time frame: 30 months

08

Results

Posted Feb 6, 2017

Participant flow

Between May 2008 and October 2001, 3,277 participants were pre-registered. Of those, 900 participants had a documented FLT3 mutation. 717 participants were enrolled onto this study.

Participant flow — Overall Study
MilestoneInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Started360357
Completed6951
Not completed291306
Withdrew: Adverse event3222
Withdrew: Death1818
Withdrew: Withdrawal by subject2240
Withdrew: Induction failure2435
Withdrew: Disease progression5858
Withdrew: Alternative therapy109107
Withdrew: Other disease or participant decisions2323
Withdrew: Never treated53

Outcome measures

PrimaryOverall Survival (OS)

Overall survival (OS) was defined as the time interval from randomization to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method.

Time frame:
Duration of study (Up to 10 years)
Reported as:
Median · months
Overall Survival (OS)
monthsInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Overall Survival (OS)74.7 (31.5 to NA)25.6 (18.6 to 42.9)
Statistical analysis
  • Induction and Consolidation Chemotherapy Plus Midostaurin vs Induction and Consolidation Chemotherapy Plus Placebo · 1-sided stratified log-rank · p = 0.009 · Hazard ratio (hr): 0.78 · 95% CI 0.63 to 0.96
SecondaryEvent- Free Survival

Event free survival (EFS) was defined as the time from randomization until the earliest qualifying event, including: failure to obtain a CR on or before 60 days of initiation of protocol therapy; relapse; or death from any cause. Patients alive and event free at the time of analysis were censored on the date of last clinical assessment. The median EFS with 95% CI was estimated using the Kaplan-Meier method. Due to a higher than expected transplant rate, EFS was promoted to be a key secondary endpoint.

Time frame:
Duration of study (Up to 10 years)
Reported as:
Median · months
Event- Free Survival
monthsInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Event- Free Survival8.2 (5.4 to 10.7)3.0 (1.9 to 5.9)
Statistical analysis
  • Induction and Consolidation Chemotherapy Plus Midostaurin vs Induction and Consolidation Chemotherapy Plus Placebo · 1-sided stratified log rank · p = 0.0024 · Hazard ratio (hr): 0.78 · 95% CI 0.66 to 0.93
SecondaryOverall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant

Overall survival (OS) was defined as the time interval from randomization to death from any cause. Any participants who received a stem cell transplant were censored at the time of transplant. The median OS with 95% CI was estimated using the Kaplan-Meier method.

Time frame:
Duration of study (Up to 10 years)
Reported as:
Median · months
Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant
monthsInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the TransplantNA (NA to NA)NA (27.4 to NA)
SecondaryComplete Response Rate

Percentage of participants who achieved a complete response (CR). A CR was defined as normalization of blood counts and a marrow showing less than 5% blasts occurring on or before day 60.

Time frame:
Induction therapy (up to 60 days)
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Complete Response Rate59 (54 to 64)54 (48 to 59)
Statistical analysis
  • Induction and Consolidation Chemotherapy Plus Midostaurin vs Induction and Consolidation Chemotherapy Plus Placebo · Fisher Exact · p = 0.15
SecondaryDisease-free Survival (DFS)

Disease free survival (DFS) is defined as the time from documentation of first CR at any time to the first of relapse or death from any cause in participants who achieved a CR.

Time frame:
Duration of study (Up to 10 years)
Reported as:
Median · months
Disease-free Survival (DFS)
monthsInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Disease-free Survival (DFS)26.7 (19.4 to NA)15.5 (11.3 to 23.5)
Statistical analysis
  • Induction and Consolidation Chemotherapy Plus Midostaurin vs Induction and Consolidation Chemotherapy Plus Placebo · 1-sided stratified log rank · p = 0.0049
SecondaryDFS Rate One Year After Completing the Planned Continuation Phase
Time frame:
30 months

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction and Consolidation Chemotherapy Plus Midostaurin—157/355 (44.2%)321/355 (90.4%)
Induction and Consolidation Chemotherapy Plus Placebo—154/354 (43.5%)324/354 (91.5%)
Most frequent serious events
Showing 10 of 350
Most frequent serious events
EventInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Platelet count decreasedInvestigations155/355146/354
Hemoglobin decreasedBlood and lymphatic system disorders154/355148/354
Neutrophil count decreasedInvestigations145/355146/354
Febrile neutropeniaBlood and lymphatic system disorders105/355110/354
FatigueGeneral disorders95/35598/354
NauseaGastrointestinal disorders98/35591/354
DiarrheaGastrointestinal disorders89/35589/354
VomitingGastrointestinal disorders70/35565/354
Rash desquamatingSkin and subcutaneous tissue disorders59/35566/354
Leukocyte count decreasedInvestigations41/35547/354
Most frequent other events
Showing 10 of 379
Most frequent other events
EventInduction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus Placebo
Platelet count decreasedInvestigations311/355313/354
Hemoglobin decreasedBlood and lymphatic system disorders312/355311/354
Neutrophil count decreasedInvestigations308/355308/354
NauseaGastrointestinal disorders258/355226/354
Febrile neutropeniaBlood and lymphatic system disorders246/355238/354
DiarrheaGastrointestinal disorders228/355219/354
FatigueGeneral disorders221/355220/354
Rash desquamatingSkin and subcutaneous tissue disorders201/355200/354
VomitingGastrointestinal disorders188/355168/354
Ear, nose and throat examination abnormalGastrointestinal disorders112/355112/354

Baseline characteristics

Age, Continuous
Age, Continuous(years)Induction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus PlaceboTotal
Median47.1 (19 to 59.8)48.6 (18 to 60.9)47.9 (18.0 to 60.9)
Sex: Female, Male
Sex: Female, Male(Participants)Induction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus PlaceboTotal
Female186212398
Male174145319
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus PlaceboTotal
Hispanic or Latino9716
Not Hispanic or Latino103107210
Unknown or Not Reported248243491
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus PlaceboTotal
American Indian or Alaska Native011
Asian8513
Native Hawaiian or Other Pacific Islander000
Black or African American8917
White147128275
More than one race213
Unknown or Not Reported195213408
Region of Enrollment
Region of Enrollment(participants)Induction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus PlaceboTotal
Canada4913
United States117106223
Germany148157305
Belgium358
France325
Netherlands325
Australia022
Spain71522
Austria7512
Italy6144105
Czech Republic5611
Slovakia224
Hungary022
FLT3 mutational subtype
FLT3 mutational subtype(participants)Induction and Consolidation Chemotherapy Plus MidostaurinInduction and Consolidation Chemotherapy Plus PlaceboTotal
TKD (No ITD)8181162
ITD Allelic ratio <0.7171170341
ITD Allelic ratio >=0.7108106214
09

Study locations

176 sites
  • UAB Comprehensive Cancer Center
    Birmingham, Alabama 35294, United States
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • University of California Davis Cancer Center
    Sacramento, California 95817, United States
  • Aurora Presbyterian Hospital
    Aurora, Colorado 80012, United States
  • Boulder Community Hospital
    Boulder, Colorado 80301-9019, United States
  • Penrose Cancer Center at Penrose Hospital
    Colorado Springs, Colorado 80933, United States
  • St. Anthony Central Hospital
    Denver, Colorado 80204, United States
  • Porter Adventist Hospital
    Denver, Colorado 80210, United States
  • Presbyterian - St. Luke's Medical Center
    Denver, Colorado 80218, United States
  • St. Joseph Hospital
    Denver, Colorado 80218, United States
  • Rose Medical Center
    Denver, Colorado 80220, United States
  • CCOP - Colorado Cancer Research Program
    Denver, Colorado 80224-2522, United States
  • Swedish Medical Center
    Englewood, Colorado 80110, United States
  • North Colorado Medical Center
    Greeley, Colorado 80631, United States
  • Sky Ridge Medical Center
    Lone Tree, Colorado 80124, United States
  • Hope Cancer Care Center at Longmont United Hospital
    Longmont, Colorado 80501, United States
  • McKee Medical Center
    Loveland, Colorado 80539, United States
  • North Suburban Medical Center
    Thornton, Colorado 80229, United States
  • Exempla Lutheran Medical Center
    Wheat Ridge, Colorado 80033, United States
  • Helen and Harry Gray Cancer Center at Hartford Hospital
    Hartford, Connecticut 06102-5037, United States
  • Tunnell Cancer Center at Beebe Medical Center
    Lewes, Delaware 19958, United States
  • CCOP - Christiana Care Health Services
    Newark, Delaware 19713, United States
  • University of Florida Shands Cancer Center
    Gainesville, Florida 32610-0232, United States
  • Memorial Cancer Institute at Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Baptist Cancer Institute - Jacksonville
    Jacksonville, Florida 32207, United States
  • Florida Hospital Cancer Institute at Florida Hospital Orlando
    Orlando, Florida 32803-1273, United States
  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
    Tampa, Florida 33612-9497, United States
  • MBCCOP - Medical College of Georgia Cancer Center
    Augusta, Georgia 30912, United States
  • Charles B. Eberhart Cancer Center at DeKalb Medical Center
    Decatur, Georgia 30033, United States
  • Medical Center of Central Georgia
    Macon, Georgia 31208, United States
  • Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
    Savannah, Georgia 31405, United States
  • Cancer Research Center of Hawaii
    Honolulu, Hawaii 96813, United States
  • Queen's Cancer Institute at Queen's Medical Center
    Honolulu, Hawaii 96813, United States
  • Illinois CancerCare - Bloomington
    Bloomington, Illinois 61701, United States
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
    Chicago, Illinois 60611-3013, United States
  • University of Illinois Cancer Center
    Chicago, Illinois 60612-7243, United States
  • University of Chicago Cancer Research Center
    Chicago, Illinois 60637-1470, United States
  • Decatur Memorial Hospital Cancer Care Institute
    Decatur, Illinois 62526, United States
  • Cardinal Bernardin Cancer Center at Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • BroMenn Regional Medical Center
    Normal, Illinois 61761, United States
  • Oncology Hematology Associates of Central Illinois, PC - Peoria
    Peoria, Illinois 61615, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46845, United States
  • McFarland Clinic, PC
    Ames, Iowa 50010, United States
  • Holden Comprehensive Cancer Center at University of Iowa
    Iowa City, Iowa 52242-1002, United States
  • Siouxland Hematology-Oncology Associates, LLP
    Sioux City, Iowa 51101, United States
  • Mercy Medical Center - Sioux City
    Sioux City, Iowa 51104, United States
  • St. Luke's Regional Medical Center
    Sioux City, Iowa 51104, United States
  • Lucille P. Markey Cancer Center at University of Kentucky
    Lexington, Kentucky 40536-0093, United States
  • Tulane Cancer Center Office of Clinical Research
    Alexandria, Louisiana 71315-3198, United States
  • Feist-Weiller Cancer Center at Louisiana State University Health Sciences
    Shreveport, Louisiana 71130-3932, United States
  • Greenebaum Cancer Center at University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Boston University Cancer Research Center
    Boston, Massachusetts 02118, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Baystate Regional Cancer Program at D'Amour Center for Cancer Care
    Springfield, Massachusetts 01199, United States
  • Battle Creek Health System Cancer Care Center
    Battle Creek, Michigan 49017, United States
  • Mecosta County Medical Center
    Big Rapids, Michigan 49307, United States
  • Butterworth Hospital at Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • CCOP - Grand Rapids
    Grand Rapids, Michigan 49503, United States
  • Lacks Cancer Center at Saint Mary's Health Care
    Grand Rapids, Michigan 49503, United States
  • Borgess Medical Center
    Kalamazoo, Michigan 49001, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007-3731, United States
  • Bronson Methodist Hospital
    Kalamazoo, Michigan 49007, United States
  • Providence Cancer Institute at Providence Hospital - Southfield Campus
    Southfield, Michigan 48075, United States
  • Munson Medical Center
    Traverse City, Michigan 49684, United States
  • Metro Health Hospital
    Wyoming, Michigan 49519, United States
  • Fairview Ridges Hospital
    Burnsville, Minnesota 55337, United States
  • Mercy and Unity Cancer Center at Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
  • Fairview Southdale Hospital
    Edina, Minnesota 55435, United States
  • Mercy and Unity Cancer Center at Unity Hospital
    Fridley, Minnesota 55432, United States
  • HealthEast Cancer Care at St. John's Hospital
    Maplewood, Minnesota 55109, United States
  • Minnesota Oncology Hematology, PA - Maplewood
    Maplewood, Minnesota 55109, United States
  • Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Hennepin County Medical Center - Minneapolis
    Minneapolis, Minnesota 55415, United States
  • Masonic Cancer Center at University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
    Robbinsdale, Minnesota 55422-2900, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • CCOP - Metro-Minnesota
    Saint Louis Park, Minnesota 55416, United States
  • Park Nicollet Cancer Center
    Saint Louis Park, Minnesota 55416, United States
  • Regions Hospital Cancer Care Center
    Saint Paul, Minnesota 55101, United States
  • United Hospital
    Saint Paul, Minnesota 55102, United States
  • Ridgeview Medical Center
    Waconia, Minnesota 55387, United States
  • Minnesota Oncology Hematology, PA - Woodbury
    Woodbury, Minnesota 55125, United States
  • University of Mississippi Cancer Clinic
    Jackson, Mississippi 39216, United States
  • Ellis Fischel Cancer Center at University of Missouri - Columbia
    Columbia, Missouri 65203, United States
  • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
    St Louis, Missouri 63110, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center
    Omaha, Nebraska 68198-6805, United States
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada 89102, United States
  • CCOP - Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • Sunrise Hospital and Medical Center
    Las Vegas, Nevada 89109, United States
  • Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756-0002, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87131-5636, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263-0001, United States
  • Monter Cancer Center of the North Shore-LIJ Health System
    Lake Success, New York 11042, United States
  • CCOP - North Shore University Hospital
    Manhasset, New York 11030, United States
  • Don Monti Comprehensive Cancer Center at North Shore University Hospital
    Manhasset, New York 11030, United States
  • Tucker Center for Cancer Care at Orange Regional Medical Center
    Middletown, New York 10940-4199, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States

Showing the first 100 of 176 sites across 2 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Stone RM, Dohner H, Ehninger G, et al.: CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. [Abstract] J Clin Oncol 29 (Suppl 15): A-TPS199, 2011.
  • Seffernick AE, Mrozek K, Nicolet D, Stone RM, Eisfeld AK, Byrd JC, Archer KJ. High-dimensional genomic feature selection with the ordered stereotype logit model. Brief Bioinform. 2022 Nov 19;23(6):bbac414. doi: 10.1093/bib/bbac414. PubMed 36184192 ↗
  • Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Dohner K, Stone RM, Dohner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 Oct 13;4(19):4945-4954. doi: 10.1182/bloodadvances.2020002904. PubMed 33049054 ↗
  • Walker CJ, Kohlschmidt J, Eisfeld AK, Mrozek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2. PubMed 31375516 ↗
  • Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 Jun 11;3(11):1714-1721. doi: 10.1182/bloodadvances.2018026112. PubMed 31171508 ↗
  • Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guerin A, Li N, Joseph G. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States. Pharmacoeconomics. 2019 Feb;37(2):239-253. doi: 10.1007/s40273-018-0732-4. PubMed 30382485 ↗
  • Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23. PubMed 28644114 ↗
  • Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep;26(9):2061-8. doi: 10.1038/leu.2012.115. Epub 2012 Apr 27. PubMed 22627678 ↗
11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2008 to primary completion in Jul 2016, 99 months.

Results were first posted in Feb 2017, 7 months after primary completion.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's 99 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 2, 2008
StartActual
Apr 2008
Primary completionActual
Jul 2016
CompletionActual
Mar 28, 2022
Results first posted
Feb 6, 2017
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 21, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis · St Louis, United States
  • Mountainview Medical · Berlin Corners, United States
Show 2 removed
  • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis · Saint Louis, United States
  • Mountainview Medical · Berlin, United States
Oct 21, 2026
Study completion
Set to Mar 28, 2022 (actual)
Oct 21, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 36184192 ↗
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 36184192 ↗
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis · St Louis, United States
    • Mountainview Medical · Berlin Corners, United States
    Show 2 removed
    • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis · Saint Louis, United States
    • Mountainview Medical · Berlin, United States
    Study completion Set to Mar 28, 2022 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT00651261
Responsible party
Sponsor
First posted
Apr 2, 2008
Start date
Apr 2008
Primary completion
Jul 2016
Completion
Mar 28, 2022
Results posted
Feb 6, 2017
Last update
Oct 21, 2026

Study contacts

Richard M. Stone, MD
study chair · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midostaurin

Start the discussion